Hester Biosciences Ltd
Hester Biosciences Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
The company expects a recovery and pickup in the Animal Healthcare division starting Q4 FY26, aiming for a more balanced revenue mix closer to a 50:50 split between Poultry and Animal Health segments in the long term. Focus on strengthening Animal Health division and biologicals, expected to pick up alongside Poultry segment.
From Hester Biosciences Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company expects a recovery and pickup in the Animal Healthcare division starting Q4 FY26, aiming for a more balanced revenue mix closer to a 50:50 split between Poultry and Animal Health segments in the long term.
- Poultry Healthcare showed strong growth, with sustained demand and 41% Q4 growth, indicating ongoing momentum.
- Focus on expanding market penetration both domestically and in export markets, especially in Africa, with strategic emphasis on biologicals and vaccine portfolio strengthening.
- Capacity expansions like Fill-Finish and BSL-3 facilities enhance product capacity and provide scalability without immediate need for new capital expenditure.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Hester Biosciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Hester Biosciences capitalized Fill-Finish and BSL-3 facilities during the year as part of manufacturing and infrastructure expansion to enhance capacity and flexibility for domestic and export markets.
- Optimization initiatives for BSL-3 facility are ongoing to improve utilization efficiency and operating costs aligned with current operational and scale-up needs.
- No definitive plan to allocate further capital expenditure currently, but evolving regulatory requirements and new technologies may necessitate future investments.
- Company aims to optimize utilization of installed capacities rather than immediately expanding further.
- Strategic focus includes strengthening biologicals portfolio, improving capacity utilization, and expanding market penetration.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Hester Biosciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The Animal Healthcare division faced delays in tender-led immunization programs during FY26 due to timing issues beyond the company's control.
- Execution of tender orders started picking up from Q4 FY26 onwards.
- Demand visibility for Animal Healthcare tender programs remains strong but dependent on country-level rollout schedules.
- The company is focusing on strengthening market penetration and presence in the Animal Healthcare segment.
2 more points management made on order book & pipeline
Hester Biosciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹100 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Hester Bios's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
- Morepen Laboratories Ltd (Q4 FY26)
472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…
- Themis Medicare Ltd (Q4 FY26)
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…
Frequently Asked Questions
What were Hester Biosciences Ltd Q4 FY26 results?
The company expects a recovery and pickup in the Animal Healthcare division starting Q4 FY26, aiming for a more balanced revenue mix closer to a 50:50 split between Poultry and Animal Health segments in the long term. Focus on strengthening Animal Health division and biologicals, expected to pick up alongside Poultry segment.
What is Hester Biosciences Ltd share price analysis?
Hester Biosciences Ltd currently shows a neutral. The stock trades at a P/E of 38.7 with a market cap of ₹2,054 Cr. Investors should review the full earnings analysis for detailed insights.
Is Hester Biosciences Ltd planning capital expenditure?
Hester Biosciences capitalized Fill-Finish and BSL-3 facilities during the year as part of manufacturing and infrastructure expansion to enhance capacity and flexibility for domestic and export markets.
Keep Hester Biosciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.